TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01670474
Drug: rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
Study: NCT00467272
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
Study: NCT04198467
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
Study: NCT02848560
Drug: Hyperpolarized Xenon
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled contrast for MRI occurring at each of 4 visits.
Study: NCT01593020
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
Study: NCT01593020
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
Study: NCT01593020
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
Study: NCT01593020
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
Study: NCT01841515
Drug: Desmopressin administration
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02170337
Drug: AMG 282
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
Study: NCT00640588
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arm 1: 600 mg/day, oral telbivudina for 24 weeks
Study: NCT01259557
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 2 times, Intra-muscular injection, Maximum dosage total 60U
Study: NCT00145470
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
Study: NCT00258609
Drug: Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00073255
Drug: hokt3g1 (ALA-ALA)
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02190708
Drug: PQ912
Normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: from day2 up to day6 twice daily oral dose of PQ912
Study: NCT02190708
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single oral dose on day1 and day 6
Study: NCT02190708
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose on day1 and day6
Study: NCT04124887
Drug: Sodium Fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
Study: NCT04124887
Drug: Tricalcium Phosphate
Normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
Study: NCT04124887
Drug: Casein phosphopeptide amorphous calcium phosphate
Normalized name: caseins
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
Study: NCT01333800
Drug: Beclomethasone
Normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 to 400 mcg per day for 6 months
Study: NCT01333800
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 to 160 mcg per day for 6 months
Study: NCT04773431
Drug: LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
Study: NCT01183598
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: maintenance dose
Study: NCT04379869
Drug: NNZ-2591
Normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of NNZ-2591
Study: NCT00003087
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003087
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05750043
Drug: bi-annual CDTI
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention
Study: NCT02063659
Drug: Telotristat etiprate
Normalized name: Telotristat etiprate
DrugBank: Telotristat (DB14218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telotristat etiprate tablets
Study: NCT01297894
Drug: colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistimethate sodium 2.5-5mg/kg of colistin base
Study: NCT01297894
Drug: colistin plus fosfomycin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
Study: NCT01541059
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
Study: NCT01298076
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF drug for intravitreal injection
Study: NCT01298076
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Slow-release steroid formulation for intravitreal injection
Study: NCT01000805
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
Study: NCT01447706
Drug: MM-121
Normalized name: 2X-121
DrugBank: 2X-121 (DB16063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM-121 (SAR256212) (IV)
Study: NCT01447706
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard dosing Paclitaxel (IV)
Study: NCT06046196
Drug: Sarpogrelate SR
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate SR 300mg, once a daily, for 24weeks
Study: NCT06046196
Drug: Sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 100mg, 3 times a day, for 24weeks
Study: NCT02788019
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
Study: NCT00005974
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
Study: NCT01647932
Drug: hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
Study: NCT02961634
Drug: Ciclopirox 8%
Normalized name: CICLOPIROX 8% SOLN,TOP
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox 8% is a glaze used in the treatment of onychomycosis
Study: NCT03345095
Drug: Marizomib
Normalized name: Marizomib
DrugBank: Marizomib (DB11762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Marizomib
Study: NCT03345095
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Administration of Temozolomide
Study: NCT02542943
Drug: Standard fluoride toothpaste
Normalized name: sodium fluoride Toothpaste [Fluoridex]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000ppm fluoride as sodium monofluorophosphate
Study: NCT03570970
Drug: Banapenem
Normalized name: Benapenem
DrugBank: Benapenem (DB18883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banapenem to be used anti-infection
Study: NCT03220074
Drug: Oral Tablet
Normalized name: Oral Tablet
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: study drug given and monitored for efficacy and tolerability
Study: NCT04207736
Drug: Reproxalap Ophthalmic Solution (0.25%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
Study: NCT04207736
Drug: Vehicle Ophthalmic Solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
Study: NCT00002866
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002866
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00070486
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT00070486
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT00070486
Drug: zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given PO
Study: NCT02704052
Drug: Real time enoxaparin dose adjustment
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
Study: NCT02704052
Drug: Standard enoxaparin dose
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
Study: NCT03270709
Drug: Vitamin D3 450,000 IU orally
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
Study: NCT02226159
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02226159
Drug: Lidocaine with Dexamethasone
Normalized name: dexamethasone / lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01064999
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
Study: NCT03568175
Drug: JR-141
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN TRANSFERRIN RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JR-141 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 2-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN IDURONATE-2-SULFATASE, DISULFIDE WITH HUMAN-MUS MUSCULUS MONO
DrugBank: Pabinafusp alfa (DB15633)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: IV infusion, 2.0 mg/kg/week
Study: NCT01624493
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
Study: NCT01624493
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
Study: NCT01624493
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
Study: NCT01624493
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
Study: NCT01624493
Drug: BNC105P
DrugBank: BNC105 (DB06313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
Study: NCT03150875
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As 2nd line treatment to subjects with squamous NSCLC
Study: NCT00609869
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
Study: NCT00609869
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
Study: NCT00042965
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01410409
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g x 4/day
Study: NCT01410409
Drug: Burana
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg x 3/day for three weeks
Study: NCT01410409
Drug: Pantoprazol
Normalized name: Pantoprazol
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg x 1/day for three weeks
Study: NCT01702376
Drug: Retosiban 100 mg
Normalized name: atosiban
DrugBank: Retosiban (DB11818)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
Study: NCT01702376
Drug: Retosiban 800 mg
Normalized name: atosiban
DrugBank: Retosiban (DB11818)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
Study: NCT01702376
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
Study: NCT02867956
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
Study: NCT02867956
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
Study: NCT01046292
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
Study: NCT01584466
Drug: Paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary.
Study: NCT01752699
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
Study: NCT01776320
Drug: Alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
Study: NCT00195403
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 25mg Injection, 2 times/week
Study: NCT02747537
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02747537
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00713596
Drug: Fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
Study: NCT00315185
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03328364
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT03328364
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT05031234
Drug: anaesthesia with morphine
Normalized name: opium alkaloids with morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anaesthesia with morphine for patients undergoing laparoscopic colectomy
Study: NCT00978588
Drug: 6% hydroxyethyl starch 130/0.4 and 5% albumin
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
Study: NCT01358669
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60mg denosumab by injection as a single dose
Study: NCT03314324
Drug: ODM-201
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
Study: NCT03314324
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
Study: NCT02328144
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
Study: NCT01760226
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.